How can transforming growth factor beta be targeted usefully to combat liver fibrosis?
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Transforming growth factor beta-1 (TGF-beta 1) plays a pivotal role in tissue fibrogenesis. Understanding the factors that control resolution of fibrosis is critical to devising means to combat clinical fibrosis. Future challenges would include designing ways to block the fibrosis-specific actions of TGF-beta. Blockade of transforming growth factor beta (TGF-beta) activity in vivo in animal models has proven to be an effective means of inhibiting the fibrotic response to injury in various organs. Similarly, transgenic animals in which TGF-beta 1 expression is artificially enhanced show marked spontaneous fibrosis or increased fibrotic response to injury. TGF-beta is known to effect fibroplasias, not only by its well known action of increasing extracellular matrix synthesis but also by coordinately regulating key proteins which mediate connective tissue homeostasis. This includes down-regulation of interstitial collagenase and other matrix metalloproteinases and up-regulation of antiproteases such as tissue inhibitor of metalloproteinase I and plasminogen activator inhibitor. Whilst inhibition of TGF-beta activity appears to be well tolerated in rodents over several weeks, the ultimately lethal phenotype of TGF-beta 1 knockout mice warns us that this pluripotent cytokine is essential for normal health. Therefore, downstream pathways activated by TGF-beta, which might be specific for its fibrotic effects, might be more useful targets for human fibrotic disease therapy. For example, the TGF-beta response protein connective tissue growth factor may be a good target for antifibrotics but definitive evidence awaits development of suitable genetically modified animal models and specific inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Olaso, E., Labrador, J.-P., Wang, L., Ikeda, K., Eng, F. J., Klein, R., Lovett, D. H., Lin, H. C., & Friedman, S. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107571200 · Cited by 238
Müller, A., Machnik, F., Zimmermann, T., & Schubert, H. (1988) · Experimental Pathology · doi:10.1016/s0232-1513(88)80155-5 · Cited by 182
Cited by
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
TGF-β/SMAD Pathway and Its Regulation in Hepatic Fibrosis
Xu, F., Liu, C., Zhou, D., & Zhang, L. (2016) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155415627681 · Cited by 756
Nguyen, V., Taine, E. G., Meng, D., Cui, T., & Tan, W. (2024) · Nutrients · doi:10.3390/nu16070924 · Cited by 378
Role of cytokines and chemokines in non-alcoholic fatty liver disease
Braunersreuther, V. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i8.727 · Cited by 362
Tsukada, S., Parsons, C. J., & Rippe, R. A. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.014 · Cited by 357
Metadata
- Authors
- Shek, F. W., & Benyon, R. C.
- Venue
- European Journal of Gastroenterology & Hepatology
- Published
- 2004-02
- Volume
- 16
- Issue
- 2
- Pages
- 123-126
- ISSN
- 0954-691X (ISSN-L)
- OpenAlex
- W2058812022
- Cited by
- 131
- References
- 2
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How can transforming growth factor beta be targeted usefully to combat liver fibrosis? https://app.cochat.ai/papers/10.1097/00042737-200402000-00001
- The paper
- Shek, F. W., & Benyon, R. C. (2004). How can transforming growth factor beta be targeted usefully to combat liver fibrosis? European Journal of Gastroenterology & Hepatology. https://doi.org/10.1097/00042737-200402000-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.